** Shares of hydrogel developer Nexgel rise as much as 15% to $2.34 after the bell
** Company expects Q3 revenue of $2.2 mln, vs analysts est. of $2.09 mln, according to LSEG data
** Sees Q4 revenue of $2.6 mln, topping estimates of $2.47 mln
** NXGL posts preliminary Q2 revenue of $1.4 mln vs est. $1.41 mln
** The outlook does not include revenue from supply deal with AbbVie signed last year - Nexgel
** Up to last close, stock down 4.2% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments